Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9526575 | 0.90 | POLB (0.34) | POLBALDH1A1TSHRCASP1BRCA1 | |
| Noreximide SCHEMBL17875126 | 0.84 | ALDH1A1 (0.48) | POLBALDH1A1TSHRHSD17B10L3MBTL1 | |
| Noreximide SCHEMBL9073180 | 0.84 | ALDH1A1 (0.48) | POLBALDH1A1TSHRHSD17B10L3MBTL1 | |
| Noreximide SCHEMBL16664270 | 0.84 | ALDH1A1 (0.48) | POLBALDH1A1TSHRHSD17B10L3MBTL1 | |
| Noreximide SCHEMBL339739 | 0.84 | ALDH1A1 (0.48) | POLBALDH1A1TSHRHSD17B10L3MBTL1 | |
| Noreximide SCHEMBL24120970 | 0.84 | ALDH1A1 (0.48) | POLBALDH1A1TSHRHSD17B10L3MBTL1 | |
| Noreximide SCHEMBL17369118 | 0.84 | ALDH1A1 (0.48) | POLBALDH1A1TSHRHSD17B10L3MBTL1 | |
| Noreximide SCHEMBL14536593 | 0.84 | ALDH1A1 (0.48) | POLBALDH1A1TSHRHSD17B10L3MBTL1 | |
| Noreximide SCHEMBL572054 | 0.84 | ALDH1A1 (0.48) | POLBALDH1A1TSHRHSD17B10L3MBTL1 | |
| Noreximide SCHEMBL1105956 | 0.84 | ALDH1A1 (0.48) | POLBALDH1A1TSHRHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024213237-A1 | CURABLE ORGANOSILOXANE-MODIFIED REACTION RESINS | WACKER CHEMIE AG (DE) | 2024-10-17 | — | — | WO | claimed |
| EP-1379249-A4 | FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | claimed |
| EP-1379249-A1 | FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002067939-A1 | FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-06 | — | — | WO | claimed |
| EP-0229391-B1 | PIPERIDINE DERIVATE, ITS USE AND PHARMACEUTICAL COMPOSITION CONTAINING IT | Eisai Co., Ltd. (JP) | 1992-07-29 | — | — | EP | claimed |
| WO-2024213237-A1 | CURABLE ORGANOSILOXANE-MODIFIED REACTION RESINS | WACKER CHEMIE AG (DE) | 2024-10-17 | — | — | WO | disclosed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-20080267860-A1 | Crystalline Microporous Material Of Zeolitic Nature | ALBEMARLE NETHERLANDS B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| US-20080267860-A1 | Crystalline Microporous Material Of Zeolitic Nature | ALBEMARLE NETHERLANDS B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-7192967-B1 | Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agents | ASTELLAS PHARMA GMBH (DE) | 2007-03-20 | — | — | US | disclosed |
| EP-1604653-A1 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-20040116457-A1 | Agents for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| EP-0229391-B1 | PIPERIDINE DERIVATE, ITS USE AND PHARMACEUTICAL COMPOSITION CONTAINING IT | Eisai Co., Ltd. (JP) | 1992-07-29 | — | — | EP | disclosed |
| US-3941746-A | Containing hindered phenolic norbornane-2,3-dicarboximides stabilized compositions | CIBA-GEIGY CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | POLB 1855/4885ALDH1A1 1143/4885TSHR 4261/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | POLB 2405/4885ALDH1A1 1185/4885TSHR 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.